Valproic acid (as semisodium valproate)
Brand: Depakote®
NICE TA:
Indication: Manic episodes associated with bipolar disorder
Disease category: Central nervous system
Commissioning responsibility: CCG
PbR excluded: No
Background
LMMG is adopting the local decision made prior to April 2013
Update March 2016 — there is a risk of abnormal pregnancy outcomes following maternal use. See DoH Drug Safety Alert (in supporting documents) for more information.
Recommendation
LMMG recommendation: Amber0
Click here to find the definitions for the colour classifications
Reason for decision: The colour classification was determined as part of the collaborative work between LCFT and medicines Management leads. Local pathways and patient safety were taken into consideration.
Supporting documents:
MHRA Drug Safety Update - Medicines related to valproate: risk of abnormal pregnancy outcomes
Decisions of Lancashire local decision making groups:
NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
---|---|---|---|---|---|
Amber0 |
Amber0 |